EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.

View source ↗

Summary

EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decision dated 9 January …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Macular Edema
• Pathologic Myopia
• Wet Age-related Macular Degeneration

Drugs mentioned

• Rimmyrah (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization. MAH: Qilu Pharma Spain S.L.. Decision date: 09/01/2026